Articles From: FBL Financial Group Reports Second Quarter 2014 Results to FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B


FBL Financial Group, Inc. (NYSE: FFG): Financial Highlights (Dollars in thousands, except per share data) FBL Financial Group, Inc. (NYSE: FFG) today reported net income attributable to FBL for the second quarter of 2014 of $28.6 million, or $1.14 per diluted common share compared to $29.6 million, or $1.13 per diluted common share, for the second quarter of 2013.
Sign-up for FBL Financial Group Reports Second Quarter 2014 Results investment picks
FBL Financial Group, Inc. (NYSE:FFG) will announce its second quarter 2014 earnings after the close of the market on Thursday, July 31, 2014.
Sign-up for FBL Financial Group Schedules Second Quarter 2014 Earnings Release Date, Conference Call and Webcast investment picks
FBL Financial Group, Inc. (NYSE:FFG) today announced that Kathleen Till Stange, Corporate and Investor Relations Vice President, will present at the 2014 InvestMNt Conference sponsored by CFA Society Minnesota.
Sign-up for FBL Financial Group to Present at 2014 InvestMNt Conference investment picks
FBL Financial Group, Inc. (NYSE:FFG) today announced that Donald J.
Sign-up for FBL Financial Group to Present at Keefe, Bruyette & Woods Insurance Conference investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR & Co. Announces Final Results of Self-Tender Offer investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR & Co. Announces Preliminary Results of Self-Tender investment picks
ARLINGTON, Va., July 21, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR & Co. Announces Self Tender Offer to Purchase up to One Million Shares investment picks
ARLINGTON, Va., July 24, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR & Co. Commences Self Tender Offer to Purchase Up to One Million Shares investment picks
ARLINGTON, Va., Sept.
Sign-up for FBR Announces Additions to Trading Team investment picks
ARLINGTON, Va., July 23, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR Announces Inaugural Healthcare Conference investment picks
ARLINGTON, Va., Sept.
Sign-up for FBR Announces Margery Fischbein Joins Investment Banking Team investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR Inaugural Healthcare Conference to Feature Thought Leadership Panel Discussions investment picks
ARLINGTON, Va., July 15, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR Reports Second Quarter Financial Results investment picks
ARLINGTON, Va., July 2, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR to Report Second Quarter 2014 Financial Results investment picks
2014/8/1
FCB Financial Holdings, Inc. (formerly known as Bond Street Holdings, Inc.) (the "Company") (NYSE: FCB) announced the pricing of its initial public offering of 7,520,000 shares of Class A common stock at a public offering price of $22.00 per share.
Sign-up for FCB Financial Holdings, Inc. Announces the Pricing of Its Initial Public Offering investment picks
FCB Financial Holdings, Inc. (NYSE: FCB) announced today that the underwriters of its initial public offering of 7,520,000 shares of its common stock that closed on August 6, 2014 have partially exercised their option to purchase an additional 720,000 shares of common stock from FCB Financial Holdings, Inc. at the initial public offering price of $22.00 per share, less underwriting discounts.
Sign-up for FCB Financial Holdings, Inc. Announces Underwriters’ Exercise of Option investment picks
FCB Financial Holdings, Inc. (NYSE:FCB) (the "Company") today reported second quarter 2014 net income of $9.2 million, or $0.26 per diluted share, and core net income of $7.4 million, or $0.21 per diluted share.
Sign-up for FCB Financial Holdings, Inc. Reports Second Quarter Net Income of $9.2 Million, or $0.26 Per Diluted Share, Up 114% Year Over Year investment picks
2014/9/10
By Gautham Nagesh Wireless carriers could soon be subject to new rules on how they handle content on their networks, Federal Communications Chairman Tom Wheeler suggested in a speech to the industry on Tuesday.
Sign-up for FCC chairman: Broadband rules could cover wireless networks investment picks
Signs Business Collaboration in South Korea with Wonik Corporation Second Quarter 2014 Conference Call Friday August 15th at 9:00 am BRIDGEWATER, N.J. , Aug.
Sign-up for FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1133903&ProfileId=051205&sourceType=1 SAN DIEGO, CA --
Sign-up for FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe investment picks
- Toujeo dossier already accepted by EMA - PARIS , July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin.
Sign-up for FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo® investment picks
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted investment picks
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter’s investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
Sign-up for FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary Immunodeficiency investment picks
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 8 to 5 that the available data support the approval of Natpara® (rhPTH [1-84]) for the long-term treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH.
Sign-up for FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism investment picks
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN™ (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails.
Sign-up for FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails investment picks
2014/9/16
By Razak Musah Baba The U.S. Food and Drug Administration approved a once-daily constipation drug from AstraZeneca PLC (AZN, AZN.LN) and Nektar Therapeutics (NKTR) for adult patients with chronic, non-cancer pain.
Sign-up for FDA Approves AstraZeneca, Nektar Constipation Drug--Update investment picks
Baxter International, Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN ® [Albumin (Human)], USP, 5% Solution.
Sign-up for FDA Approves Baxter’s FLEXBUMIN 5%, First and Only 5% Human Albumin Solution in a Flexible Container investment picks
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]. HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion to deliver a full therapeutic dose of IG.
Sign-up for FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency investment picks
Baxter International Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved RIXUBIS [Coagulation Factor IX (Recombinant)] for routine prophylactic treatment, control and prevention of bleeding episodes, and perioperative management in children with hemophilia B.
Sign-up for FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: FBL Financial Group Reports Second Quarter 2014 Results to FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices